Literature DB >> 1678031

Different interactions of platelets with arterial and venous coronary bypass vessels.

Z H Yang1, P Stulz, L von Segesser, E Bauer, M Turina, T F Lüscher.   

Abstract

We studied the interaction of platelets with the wall of human internal mammary arteries and saphenous veins, suspended in organ chambers for measurement of isometric tension. Vessels were obtained during coronary bypass surgery and cut into 5 mm rings; in some the endothelium was chemically removed. Rings from several patients were randomly chosen for each experiment, and in each ring six concentrations of platelets (from healthy blood donors; 1-75 x 10(3)/microliters) were tested consecutively and concentration-response curves constructed; the areas under these curves were used for statistical comparisons. In rings of internal mammary artery contracted in response to noradrenaline, aggregating platelets induced endothelium-dependent relaxation which was prevented by apyrase (0.67 U/ml ADPase activity) and L-NG-monomethylarginine (1 mmol/l). By contrast, in saphenous vein rings contracted in response to noradrenaline, aggregating platelets induced only a further increase in tension. In quiescent vessels, the platelet-induced contraction did not occur in arteries with endothelium but that in veins was greater and facilitated by endothelium. Preincubation of platelets with aspirin (10 mumol/l) reduced the contraction in both vessels, but contraction was abolished only in the presence of both the thromboxane receptor antagonist SQ-30741 and the serotoninergic (5HT2) receptor antagonist ketanserin. These findings show that platelet-derived ADP causes release of nitric oxide by the endothelium of internal mammary artery but not of saphenous vein; thromboxane A2 and serotonin mediate contraction in vein but not artery with endothelium. These differences may contribute to differences in graft function and the clinical efficacy of antiplatelet drugs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1678031     DOI: 10.1016/0140-6736(91)91571-b

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  8 in total

Review 1.  Endogenous and exogenous nitrates and their role in myocardial ischaemia.

Authors:  T F Lüscher
Journal:  Br J Clin Pharmacol       Date:  1992       Impact factor: 4.335

2.  5-Hydroxytryptamine-induced contractions of the human isolated saphenous vein: involvement of 5-HT2 and 5-HT1D-like receptors, and a comparison with grafted veins.

Authors:  W A Bax; D Van Heuven-Nolsen; E Bos; M L Simoons; P R Saxena
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-05       Impact factor: 3.000

Review 3.  Endothelial vasomotor regulation in health and disease.

Authors:  N R Searle; P Sahab
Journal:  Can J Anaesth       Date:  1992-10       Impact factor: 5.063

Review 4.  The endothelial L-arginine/nitric oxide pathway and the renal circulation.

Authors:  T F Lüscher; H A Bock
Journal:  Klin Wochenschr       Date:  1991-09-03

5.  Sumatriptan-induced saphenous venoconstriction in the anaesthetized dog through 5-HT1-like receptor activation.

Authors:  C Drieu la Rochelle; S E O'Connor
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

6.  S-nitrosoglutathione inhibits platelet activation and deposition in coronary artery saphenous vein grafts in vitro and in vivo.

Authors:  E Salas; E J Langford; M T Marrinan; J F Martin; S Moncada; A J de Belder
Journal:  Heart       Date:  1998-08       Impact factor: 5.994

7.  Resilience of the Internal Mammary Artery to Atherogenesis: Shifting From Risk to Resistance to Address Unmet Needs.

Authors:  Simon Kraler; Peter Libby; Paul C Evans; Alexander Akhmedov; Martin O Schmiady; Michael Reinehr; Giovanni G Camici; Thomas F Lüscher
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-06-10       Impact factor: 10.514

Review 8.  COVID-19 is, in the end, an endothelial disease.

Authors:  Peter Libby; Thomas Lüscher
Journal:  Eur Heart J       Date:  2020-09-01       Impact factor: 29.983

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.